Eric Schmidt

Michael Schmidt

Sudan Loganathan

Dingding Shi

Greg Harrison

Gregory Renza

Jenna Li

Kelly Shi

Leonid Timashev

- ADC Therapeutics SA announced a **$60.0 million private investment in public equity (PIPE) financing**, involving the sale of **11.3 million common shares at $4.00 per share** and **pre-funded warrants to purchase 3.8 million common shares at $3.90 per pre-funded warrant**.  **[1771910_0000950103-25-013103_dp235779_ex9901.htm:0]** 
- The company plans to use the net proceeds to **invest in the commercial expansion of ZYNLONTA®**, strengthen its balance sheet, and fund working capital and general corporate purposes.  **[1771910_0000950103-25-013103_dp235779_ex9901.htm:0]** 
- For the third quarter ended September 30, 2025, ADC Therapeutics expects **net product revenues from ZYNLONTA to be approximately $15.8 million** and reported **cash and cash equivalents totaling $234.7 million**; pro forma for the PIPE, cash and cash equivalents would have been approximately **$292.3 million**.  **[1771910_0000950103-25-013103_dp235779_ex9901.htm:0]**

ADC Therapeutics Announces $60 Million Private Placement and Preliminary Q3 2025 Results

- ADC Therapeutics SA anticipates a cash runway into **2028**.  **[1771910_0000950103-25-012514_dp235214_ex9901.htm:4]** 
- The company's FDA-approved ZYNLONTA® is indicated as monotherapy for **3L+ relapsed or refractory large B-cell lymphoma (DLBCL)**, showing a **48.3% Overall Response Rate (ORR)** and **24.8% Complete Response (CR)**.  **[1771910_0000950103-25-012514_dp235214_ex9901.htm:4]** **[1771910_0000950103-25-012514_dp235214_ex9901.htm:8]** 
- Key clinical trials for ZYNLONTA expansion include the Phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) in **2L+ DLBCL**, with topline data expected in **1H 2026**   , and the Phase 1b LOTIS-7 trial (ZYNLONTA + glofitamab) which demonstrated an **86.7% Complete Response (CR)** in efficacy evaluable r/r Large B-Cell Lymphoma patients as of April 14, 2025.   
- Investigator-initiated trials for ZYNLONTA also reported a **69.2% CR rate** in r/r Marginal Zone Lymphoma (MZL) and a **76.9% CR rate** in r/r Follicular Lymphoma (FL).  **[1771910_0000950103-25-012514_dp235214_ex9901.htm:10]** **[1771910_0000950103-25-012514_dp235214_ex9901.htm:11]** 
- The company projects ZYNLONTA's U.S. peak revenue potential to be between **$600 million and $1 billion** in DLBCL and Indolent Lymphomas, with **$200 million to $300 million** from LOTIS-5 and **$500 million to $800 million** from LOTIS-7.

ADC Therapeutics SA Updates on ZYNLONTA Clinical Development and Revenue Potential

- ADC Therapeutics is a commercial-stage antibody-drug conjugate company focused on its lead asset, **ZYNLONTA**, which is approved for diffuse large B-cell lymphoma (DLBCL) and is projected to achieve **$600 million to $1 billion** in peak sales.  **[1771910_tx_380782_0]** 
- The company anticipates key clinical readouts and regulatory milestones for ZYNLONTA within the next 6-12 months, including data from the Phase 3 **LOTIS-5 study** in second-line DLBCL and the Phase 2 **LOTIS-7 study** (ZYNLONTA + glofitamab).  **[1771910_tx_380782_0]**  Initial LOTIS-7 data showed an **87% complete response rate**.  **[1771910_tx_380782_3]** 
- ADC Therapeutics also provided updates on ZYNLONTA's progress in indolent lymphomas, with initial data showing a **97% overall response rate** and **77% complete response rate** in follicular lymphoma, and a **70% complete response rate** in marginal zone lymphoma.  **[1771910_tx_380782_5]** 
- The company reported a cash position of **$265 million** at the end of Q2, providing a cash runway into **2028**, with multiple potential revenue catalysts expected by the first half of **2027**.  **[1771910_tx_380782_6]**

ADC Therapeutics Discusses ZYNLONTA Clinical Programs and Financial Outlook

ADC Therapeutics (ADCT)